Talzenna
Advanced or Recurrent Solid Tumors
Center Trials & TreatmentPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Advanced or Recurrent Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FGF/FGFR PATHWAY INHIBITOR E7090 National Cancer Center, Japan | Phase 2 | CCC |
Tislelizumab Peking University | Phase 1 | CC |
evm16 Peking University | Phase 1 | CC |
rc48-adc Peking University | Phase 1 | CC |
Pyrotinib Peking University | Phase 1 | CC |
as1404 Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
Talzenna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →